Zacks.com on MSN8h
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
Shares of Wave Life Sciences WVE surged 53.4% on Tuesday after the company announced positive interim data from a mid-stage ...
pharmaphorum11h
Surfing on new Duchenne data, Wave charges $175m offering
Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to ...
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.
GlobalData on MSN7h
Wave’s stock swells as it eyes approval following Phase II DMD victory
The company’s stock rose by 53.37% from $5.34 at close on 23 September to $8.19 at close yesterday (24 September).
Wave Life Sciences’ WVE-N531 Shows Best-in-Class Potential in DMD Treatment, Justifying a Buy Rating
H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his ...
The Pharma Letter11h
Wave Life Sciences soars on positive DMD trial results
Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an ...
BioWorld1d
Wave Life soars on WVE-N531 phase II Duchenne data
Interim phase II data of Wave Life Sciences Ltd.’s oligonucleotide, WVE-N531, revealed “impressive” dystrophin expression, ...
Wave Life And Capricor Surge Forward With Hope - Are These Stocks In Your Portfolio?
Duchenne muscular dystrophy, or DMD, is a severe genetic disorder, typically affecting males, and is characterized by progressive ...